• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Stelara (ustekinumab) - Articles and news items

Cosentyx

Cosentyx superior to Stelara in achieving sustained skin clearance in psoriasis

Industry news / 7 March 2016 / Victoria White

In the CLEAR study, Cosentyx (secukinumab) was significantly better than Stelara (ustekinumab) in achieving PASI 100 (clear skin) response at 52 weeks…

eular

Janssen to present 17 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis at EULAR

Industry news / 11 June 2015 / Victoria White

Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR…

Novartis

Novartis to present new late-breaking Cosentyx data at AAD 2015 showing significant patient benefit in achieving clear skin

Industry news / 13 March 2015 / Novartis

Novartis announced that new results for Cosentyx(TM) (secukinumab) in moderate-to-severe plaque psoriasis, including detailed findings from the head-to-head CLEAR study and long-term data from the Phase III program, will be presented as late breaking research at the 73rd Annual Meeting of American Academy of Dermatology…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +